Responsabile Scientifico

• GARIGLIO Marisa (DiMET)

Partecipanti al progetto

• GARIGLIO Marisa (DiMET)

Titolo del progetto

• Dissecting the crosstalk between infected and bystander cells during human cytomegalovirus and Zika virus infection to discover novel pathogenetic mechanisms and therapeutical targets

Ente finanziatore

• MUR - Ministero dell'Università e Ricerca

Programma di finanziamento

• PRIN - Progetti di Ricerca di Rilevante Interesse Nazionale (dal 2020)

Bando di riferimento

• PRIN 2022 PNRR

Anno di presentazione del progetto

• 2022

Anno di approvazione del progetto

• 2023

Project ID / numero contratto

• P20222YKP8_001

Durata del progetto

• 24 mesi

Inizio del progetto

• 30/11/2023

Fine del progetto

• 29/11/2025

Ente capofila

• UNIUPO - Universita Degli Studi del Università del Piemonte Orientale "Amedeo Avogadro"

Altri partner del progetto

• UNIPD - Università degli Studi di Padova
• UNIPI - Università di Pisa

Progetto approvato - Contributo unità di ricerca del Dipartimento

• €87.802,00

Sustainable Development Goals - Agenda 2030

Keyword

• Zika virus (ZIKV)
• Virus-Induced Senescence (VIS)
• Neurotropic viruses
• Brain organoids
• Cytomegalovirus (HCMV)
• Paracrine senescence

Stato del progetto

• Approvato

Abstract

• HCMV (human cytomegalovirus) is a human beta-herpesvirus usually acquired during childhood that establishes a lifelong persistent infection. However, in immunocompromised individuals, HCMV behaves like an opportunistic pathogen that can cause life-threatening disease. It is also a leading cause of birth defects, primarily affecting the central nervous system (CNS) upon congenital infections. Similarly, congenital Zika virus (ZIKV) infections are associated with severe congenital anomalies, given that it is an RNA virus transmitted by Aedes mosquito or from mother to fetus that particularly targets neural progenitor cells. Despite this evidence, the effects of these two neurotropic viruses on neural stem/progenitor cells and neighbouring bystander uninfected cells have been poorly investigated. Since both viruses impair neurogenesis upon congenital infection, we hypothesize that they display common pathogenetic mechanisms. Recently, it has been found that both DNA or RNA viruses can evoke a form of cellular senescence defined virus-induced senescence (VIS). Cellular senescence is a state of stable cell cycle arrest associated with acquisition of the senescence-associated secretory phenotype (SASP) that in turn switches paracrine senescence in the neighboring cells. The proposing team has recently demonstrated that HCMV-infected renal primary tubular cells but not fibroblasts are capable of triggering a senescence/inflammatory loop that leads bystander non-infected cells to develop a similar senescence/inflammatory phenotype. These findings raise the intriguing possibility that HCMV-mediated paracrine senescence of epithelial cells may contribute to HCMV-related pathogenesis in the kidney and very likely other organs. In this proposal, we aim to address whether VIS and paracrine senescence in bystander uninfected cells are also involved in the development of the brain disorders evoked by HCMV or ZIKV congenital infection. An essential element of innovation in this proposal is the use of stem cell-derived brain organoids that recapitulate the developing human brain architecture, with different cell types arising over the course of organoid maturation. This proposal aims to: i) understand whether senescence and paracrine senescence, as an indirect amplifying mechanism of virus-induced damage, may also be envisaged for other HCMV-susceptible cell types, e.g. respiratory epithelial cells or cells of the neural lineage; ii) mechanistically dissect HCMV- and ZIKV-induced pathogenesis in the developing brain; and iii) molecularly and functionally characterize the crosstalk between infected and uninfected bystander cells. As targeting virus-induced senescent cells using senolytic drugs is an attractive option to selectively eliminate infected or damaged cells to create a more tolerant host response with reduced inflammation and disease, this proposal holds great potential to inspire the development of novel antiviral strategies.